Generic placeholder image

Recent Advances in Cardiovascular Drug Discovery (Discontinued)


ISSN (Print): 1574-8901
ISSN (Online): 2212-3962

Review Article

Streptokinase-A Drug for Thrombolytic Therapy: A Patent Review

Author(s): Adinarayana Kunamneni and Ravi Durvasula

Volume 9, Issue 2, 2014

Page: [106 - 121] Pages: 16

DOI: 10.2174/1574890110999150202150017

Price: $65


Accumulation of fibrin in blood vessels significantly increases thrombosis, leading to myocardial infraction and other cardiovascular diseases. Microbial enzymes are one option for curing this pathological condition. Fibrinolytic enzymes such as urokinase (UK), tissue type plasminogen activator (t-PA) and streptokinase (SK) attracted much attention for thrombolytic therapy. Among them SK is preferable in low-resource settings because it is cost-effective. Therefore, the purpose of this review is to summarize recent patents related to the occurrence, mechanism of action, physico-chemical properties, cloning and expression, production, structure, immunogenicity, chemical modification, in vivo application and clinical trials of SK. This patent review considers the properties and characteristics of SK that make it a preferred agent for thrombolytic therapy.

Keywords: Acute myocardial infarction (AMI), fibrinolysis, plasminogen activators, streptokinase (SK), thrombolytic therapy.

Next »

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy